Housset C
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
-
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
-
Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
-
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
-
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.